Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Clinical/Translational Cancer Immunotherapy

Section edited by James L. Gulley, MD, PhD and Douglas G. McNeel, MD, PhD

First-in-man clinical trials (prospective clinical data only); phase II/III clinical studies; immune monitoring investigations; tumor microenvironment; combination therapies; and cell therapies.

Page 1 of 5

  1. Patients with chronic viral infections including human immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis C (HCV) are at increased risk of developing malignancies. The safety and efficacy of ICI the...

    Authors: Neil J. Shah, Ghassan Al-Shbool, Matthew Blackburn, Michael Cook, Anas Belouali, Stephen V. Liu, Subha Madhavan, Aiwu Ruth He, Michael B. Atkins, Geoffrey T. Gibney and Chul Kim

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:353

    Content type: Research article

    Published on:

  2. Although several therapeutic options for patients with renal cell carcinoma (RCC) have been approved over recent years, including immune checkpoint inhibitors, considerable need remains for molecular biomarker...

    Authors: Rui Wang, Junying Zheng, Xiao Shao, Yuko Ishii, Amit Roy, Akintunde Bello, Richard Lee, Joshua Zhang, Megan Wind-Rotolo and Yan Feng

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:348

    Content type: Short report

    Published on:

  3. Unlike some adult cancers, most pediatric cancers are considered immunologically cold and generally less responsive to immunotherapy. While immunotherapy has already been incorporated into standard of care tre...

    Authors: Julie Voeller, Amy K. Erbe, Jacob Slowinski, Kayla Rasmussen, Peter M. Carlson, Anna Hoefges, Sabrina VandenHeuvel, Ashley Stuckwisch, Xing Wang, Stephen D. Gillies, Ravi B. Patel, Alvin Farrel, Jo Lynne Rokita, John Maris, Jacquelyn A. Hank, Zachary S. Morris…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:344

    Content type: Research article

    Published on:

  4. Expressed on activated T and natural killer cells, 4-1BB/CD137 is a costimulatory receptor that signals a series of events resulting in cytokine secretion and enhanced effector function. Targeting 4-1BB/CD137 ...

    Authors: Ezra E. W. Cohen, Michael J. Pishvaian, Dale R. Shepard, Ding Wang, Jared Weiss, Melissa L. Johnson, Christine H. Chung, Ying Chen, Bo Huang, Craig B. Davis, Francesca Toffalorio, Aron Thall and Steven F. Powell

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:342

    Content type: Research article

    Published on:

  5. Deciphering the correlation between immune-related adverse events (irAEs) categorized by organ system class and clinical benefit of immunotherapy is critical for clinical practice. The aim of this study is to ...

    Authors: Puyuan Xing, Fan Zhang, Guoqiang Wang, Yu Xu, Chengcheng Li, Shouzheng Wang, Yiying Guo, Shangli Cai, Yan Wang and Junling Li

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:341

    Content type: Review

    Published on:

  6. Accumulating preclinical data indicate that targeting the SIRPα/CD47 axis alone or in combination with existing targeted therapies or immune checkpoint inhibitors enhances tumor rejection. Although several CD4...

    Authors: Erik Voets, Marc Paradé, David Lutje Hulsik, Sanne Spijkers, Wout Janssen, Joost Rens, Inge Reinieren-Beeren, Gilbert van den Tillaart, Sander van Duijnhoven, Lilian Driessen, Maurice Habraken, Peter van Zandvoort, Joost Kreijtz, Paul Vink, Andrea van Elsas and Hans van Eenennaam

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:340

    Content type: Research article

    Published on:

  7. Regulatory T (Treg) cells have an immunosuppressive function in cancer, but the underlying mechanism of immunosuppression in the tumor microenvironment (TME) is unclear.

    Authors: Hye Ryun Kim, Hyo Jin Park, Jimin Son, Jin Gu Lee, Kyung Young Chung, Nam Hoon Cho, Hyo Sup Shim, Seyeon Park, Gamin Kim, Hong In Yoon, Hyun Gyung Kim, Yong Woo Jung, Byoung Chul Cho, Seong Yong Park, Sun Young Rha and Sang-Jun Ha

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:339

    Content type: Research article

    Published on:

  8. Paraneoplastic syndromes (PNS) are autoimmune disorders specifically associated with cancer. There are few data on anti-PD-1 or anti-PD-L1 immunotherapy in patients with a PNS. Our objective was to describe th...

    Authors: Guillaume Manson, Alexandre Thibault Jacques Maria, Florence Poizeau, François-Xavier Danlos, Marie Kostine, Solenn Brosseau, Sandrine Aspeslagh, Pauline Du Rusquec, Maxime Roger, Maud Pallix-Guyot, Marc Ruivard, Léa Dousset, Laurianne Grignou, Dimitri Psimaras, Johan Pluvy, Gilles Quéré…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:337

    Content type: Research article

    Published on:

  9. Immunotherapy is now widely established as a potent and effective treatment option across several types of cancer. However, there is increasing recognition that not all patients respond to immunotherapy, focus...

    Authors: Paolo A. Ascierto, Carlo Bifulco, Luigi Buonaguro, Leisha A. Emens, Robert L. Ferris, Bernard A. Fox, Greg M. Delgoffe, Jérôme Galon, Cesare Gridelli, Marco Merlano, Paul Nathan, Kunle Odunsi, Hideho Okada, Chrystal M. Paulos, Sandro Pignata, Kurt A. Schalper…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:332

    Content type: Review

    Published on:

  10. Pre-clinical and clinical studies have shown that the infusion of CAR T cells with a naive-like (TN) and central memory (TCM) phenotype is associated with prolonged in vivo T cell persistence and superior anti-tu...

    Authors: Alejandro Torres Chavez, Mary Kathryn McKenna, Emanuele Canestrari, Christina T. Dann, Carlos A. Ramos, Premal Lulla, Ann M. Leen, Juan F. Vera and Norihiro Watanabe

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:330

    Content type: Research article

    Published on:

  11. Programmed death-1 (PD-1) immune checkpoint blockade has achieved clinical successes in cancer therapy. However, the response rate of anti-PD-1 agents remains low. Additionally, a subpopulation of patients dev...

    Authors: Douglas D. Fang, Qiuqiong Tang, Yanhui Kong, Qixin Wang, Jiaxing Gu, Xu Fang, Peng Zou, Tao Rong, Jingwen Wang, Dajun Yang and Yifan Zhai

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:327

    Content type: Research article

    Published on:

  12. Hepatitis B virus (HBV) reactivation is a serious complication in patients with cancers and HBV infection undergoing immunosuppressant treatment or chemotherapy. However, the safety of anti-programmed cell dea...

    Authors: Xuanye Zhang, Yixin Zhou, Chen Chen, Wenfeng Fang, Xiuyu Cai, Xiaoshi Zhang, Ming Zhao, Bei Zhang, Wenqi Jiang, Zuan Lin, Yuxiang Ma, Yunpeng Yang, Yan Huang, Hongyun Zhao, Ruihua Xu, Shaodong Hong…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:322

    Content type: Research article

    Published on:

  13. Tumour-associated macrophages (TAMs) are often implicated in cancer progression but can also exert anti-tumour activities. Selective eradication of cancer-promoting (M2-like) TAM subsets is a highly sought-aft...

    Authors: Eleanor M. Scott, Egon J. Jacobus, Brian Lyons, Sally Frost, Joshua D. Freedman, Arthur Dyer, Hena Khalique, William K. Taverner, Alison Carr, Brian R. Champion, Kerry D. Fisher, Len W. Seymour and Margaret R. Duffy

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:320

    Content type: Research article

    Published on:

  14. Myasthenia gravis (MG) is a rare but life-threatening adverse event of immune checkpoint inhibitors (ICI). Given the limited evidence, data from a large cohort of patients is needed to aid in recognition and m...

    Authors: Houssein Safa, Daniel H Johnson, Van Anh Trinh, Theresa E Rodgers, Heather Lin, Maria E Suarez-Almazor, Faisal Fa’ak, Chantal Saberian, Cassian Yee, Michael A Davies, Sudhakar Tummala, Karin Woodman, Noha Abdel-Wahab and Adi Diab

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:319

    Content type: Research article

    Published on:

  15. Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. We hypothesized that B...

    Authors: Lorenza Landi, Federica D’Incà, Alain Gelibter, Rita Chiari, Francesco Grossi, Angelo Delmonte, Antonio Passaro, Diego Signorelli, Francesco Gelsomino, Domenico Galetta, Diana Giannarelli, Hector Soto Parra, Gabriele Minuti, Marcello Tiseo, Maria Rita Migliorino, Francesco Cognetti…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:316

    Content type: Research article

    Published on:

  16. The iMATRIX-atezolizumab study was a phase I/II, multicenter, open-label study designed to assess the safety and pharmacokinetics of atezolizumab in pediatric and young adult patients. We describe the pharmaco...

    Authors: Colby S. Shemesh, Pascal Chanu, Kris Jamsen, Russ Wada, Gianluca Rossato, Francis Donaldson, Amit Garg, Helen Winter, Jane Ruppel, Xin Wang, Rene Bruno, Jin Jin and Sandhya Girish

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:314

    Content type: Research article

    Published on:

  17. The standard treatment for epithelial ovarian carcinoma (EOC) is surgery followed by platinum/paclitaxel-based chemotherapy, but the overall survival rate is poor. The purpose of this study was to investigate ...

    Authors: Yu-Li Chen, Han-Wei Lin, Chung-Liang Chien, Yen-Ling Lai, Wei-Zen Sun, Chi-An Chen and Wen-Fang Cheng

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:313

    Content type: Research article

    Published on:

  18. TNF receptor family agonists and checkpoint blockade combination therapies lead to minimal tumor clearance of poorly immunogenic tumors. Therefore, a need to enhance the efficacy of this combination therapy ar...

    Authors: Jaina M. Patel, Zhihua Cui, Zhi-Fa Wen, Catherine T. Dinh and Hong-Ming Hu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:311

    Content type: Research article

    Published on:

  19. Patient derived organoids (PDOs) can be established from colorectal cancers (CRCs) as in vitro models to interrogate cancer biology and its clinical relevance. We applied mass spectrometry (MS) immunopeptidomi...

    Authors: Alice Newey, Beatrice Griffiths, Justine Michaux, Hui Song Pak, Brian J. Stevenson, Andrew Woolston, Maria Semiannikova, Georgia Spain, Louise J. Barber, Nik Matthews, Sheela Rao, David Watkins, Ian Chau, George Coukos, Julien Racle, David Gfeller…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:309

    Content type: Research article

    Published on:

  20. Despite remarkable success in the treatment of hematological malignancies, CAR T-cell therapies for solid tumors have floundered, in large part due to local immune suppression and the effects of prolonged stim...

    Authors: Bryan D. Choi, Xiaoling Yu, Ana P. Castano, Henia Darr, Daniel B. Henderson, Amanda A. Bouffard, Rebecca C. Larson, Irene Scarfò, Stefanie R. Bailey, Genevieve M. Gerhard, Matthew J. Frigault, Mark B. Leick, Andrea Schmidts, Jason G. Sagert, William T. Curry, Bob S. Carter…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:304

    Content type: Short report

    Published on:

  21. Clinical benefit of cellular immunotherapy has been shown in patients with castration-resistant prostate cancer (CRPC). We investigated the immunological response and clinical outcome of vaccination with blood-de...

    Authors: Harm Westdorp, Jeroen H. A. Creemers, Inge M. van Oort, Gerty Schreibelt, Mark A. J. Gorris, Niven Mehra, Michiel Simons, Anna L. de Goede, Michelle M. van Rossum, Alexandra J. Croockewit, Carl G. Figdor, J. Alfred Witjes, Erik H. J. G. Aarntzen, Roel D. M. Mus, Mareke Brüning, Katja Petry…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:302

    Content type: Research article

    Published on:

  22. Uveal melanoma (UM) is highly refractory to treatment with dismal prognosis in advanced stages. The value of the combined checkpoint blockade with CTLA-4 and PD-1 inhibition in metastatic UM is currently unclear.

    Authors: Markus V. Heppt, Teresa Amaral, Katharina C. Kähler, Lucie Heinzerling, Jessica C. Hassel, Markus Meissner, Nicole Kreuzberg, Carmen Loquai, Lydia Reinhardt, Jochen Utikal, Evelyn Dabrowski, Anja Gesierich, Claudia Pföhler, Patrick Terheyden, Kai-Martin Thoms, Lisa Zimmer…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:299

    Content type: Research article

    Published on:

  23. Immune checkpoint inhibitors (CPIs) are effective against a variety of malignancies but can be limited by inflammatory toxicities such as enterocolitis. Enterocolitis is typically treated with systemically act...

    Authors: Michael S. Hughes, Gabriel E. Molina, Steven T. Chen, Hui Zheng, Vikram Deshpande, Riley Fadden, Ryan J. Sullivan and Michael Dougan

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:292

    Content type: Research article

    Published on:

  24. The peculiar multiple myeloma microenvironment, characterized by up-regulated levels of several inflammatory chemokines, including the CXCR3 receptor ligands CXCL9 and CXCL10, limits NK cell positioning into t...

    Authors: Valentina Bonanni, Fabrizio Antonangeli, Angela Santoni and Giovanni Bernardini

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:290

    Content type: Research article

    Published on:

  25. The introduction of immune checkpoint inhibitors has led to a survival benefit in patients with advanced melanoma; however data on the adoption of immunotherapy in the community are scarce.

    Authors: Marieke J. Krimphove, Karl H. Tully, David F. Friedlander, Maya Marchese, Praful Ravi, Stuart R. Lipsitz, Kerry L. Kilbridge, Adam S. Kibel, Luis A. Kluth, Patrick A. Ott, Toni K. Choueiri and Quoc-Dien Trinh

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:289

    Content type: Research article

    Published on:

  26. The treatment of endometrial cancer (EC), the most common gynecological cancer, is currently hampered by the toxicity of current cytotoxic agents, meaning novel therapeutic approaches are urgently required.

    Authors: Gareth D. Healey, Belen Pan-Castillo, Jezabel Garcia-Parra, Julia Davies, Shaun Roberts, Eilir Jones, Kalyan Dhar, Sarika Nandanan, Nasima Tofazzal, Luke Piggott, Richard Clarkson, Gillian Seaton, Asa Frostell, Tim Fagge, Colin McKee, Lavinia Margarit…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:280

    Content type: Research article

    Published on:

  27. Prostate cancer responds poorly to current immunotherapies. Epigenetic therapies such as BET Bromodomain inhibition can change the transcriptome of tumor cells, possibly making them more immunogenic and thus s...

    Authors: Wendy Mao, Ali Ghasemzadeh, Zachary T. Freeman, Aleksandar Obradovic, Matthew G. Chaimowitz, Thomas R. Nirschl, Emily McKiernan, Srinivasan Yegnasubramanian and Charles G. Drake

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:277

    Content type: Research article

    Published on:

  28. Gene-modified autologous T cells expressing NY-ESO-1c259, an affinity-enhanced T-cell receptor (TCR) reactive against the NY-ESO-1-specific HLA-A*02-restricted peptide SLLMWITQC (NY-ESO-1 SPEAR T-cells; GSK 794),...

    Authors: Indu Ramachandran, Daniel E. Lowther, Rebecca Dryer-Minnerly, Ruoxi Wang, Svetlana Fayngerts, Daniel Nunez, Gareth Betts, Natalie Bath, Alex J. Tipping, Luca Melchiori, Jean-Marc Navenot, John Glod, Crystal L. Mackall, Sandra P. D’Angelo, Dejka M. Araujo, Warren A. Chow…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:276

    Content type: Research article

    Published on:

  29. Antibodies targeting programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have shown clinical activity in the treatment of metastatic renal cell carcinoma (mRCC). This phase Ib cohort of the JAVELIN ...

    Authors: Ulka Vaishampayan, Patrick Schöffski, Alain Ravaud, Christian Borel, Julio Peguero, Jorge Chaves, John C. Morris, Nuria Kotecki, Martin Smakal, Dongli Zhou, Silke Guenther, Marcis Bajars and James L. Gulley

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:275

    Content type: Research article

    Published on:

  30. Immunotherapy using checkpoint inhibitors, especially PD-1/PD-L1 inhibitors, has now evolved into the most promising therapy for cancer patients. However, most of these inhibitors are monoclonal antibodies, an...

    Authors: Hao Liu, Zhen Zhao, Li Zhang, Yuanke Li, Akshay Jain, Ashutosh Barve, Wei Jin, Yanli Liu, John Fetse and Kun Cheng

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:270

    Content type: Research article

    Published on:

  31. Thymic epithelial tumors are PD-L1–expressing tumors of thymic epithelial origin characterized by varying degrees of lymphocytic infiltration and a predisposition towards development of paraneoplastic autoimmu...

    Authors: Arun Rajan, Christopher R. Heery, Anish Thomas, Andrew L. Mammen, Susan Perry, Geraldine O’Sullivan Coyne, Udayan Guha, Arlene Berman, Eva Szabo, Ravi A. Madan, Leomar Y. Ballester, Stefania Pittaluga, Renee N. Donahue, Yo-Ting Tsai, Lauren M. Lepone, Kevin Chin…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:269

    Content type: Research article

    Published on:

  32. The tumor microenvironment exists in a state of dynamic equilibrium, in which a balance of agonist and antagonist signals govern the anti-tumor immune responses. Previous studies have shown that chemotherapy c...

    Authors: Tae Heung Kang, Chih-Ping Mao, Young Seob Kim, Tae Woo Kim, Andrew Yang, Brandon Lam, Ssu-Hsueh Tseng, Emily Farmer, Yeong-Min Park and Chien-Fu Hung

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:260

    Content type: Short report

    Published on:

  33. Adrenocortical carcinoma (ACC) is a rare malignancy without good treatment options. There are limited data about the use of immunotherapy in ACC. We investigated the efficacy and safety of pembrolizumab in pat...

    Authors: Mouhammed Amir Habra, Bettzy Stephen, Matthew Campbell, Kenneth Hess, Coya Tapia, Mingxuan Xu, Jordi Rodon Ahnert, Camilo Jimenez, Jeffrey E. Lee, Nancy D. Perrier, Russell R. Boraddus, Shubham Pant, Vivek Subbiah, David S. Hong, Abdulrazzak Zarifa, Siqing Fu…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:253

    Content type: Research article

    Published on:

  34. Immune checkpoint inhibitors (ICIs) confer a survival benefit in many cancer types. Given that the survival outcome for cancer of unknown primary site (CUP) remains poor, we investigated the potential of CUP f...

    Authors: Koji Haratani, Hidetoshi Hayashi, Takayuki Takahama, Yasushi Nakamura, Shuta Tomida, Takeshi Yoshida, Yasutaka Chiba, Takahiro Sawada, Kazuko Sakai, Yoshihiko Fujita, Yosuke Togashi, Junko Tanizaki, Hisato Kawakami, Akihiko Ito, Kazuto Nishio and Kazuhiko Nakagawa

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:251

    Content type: Research article

    Published on:

  35. Antibody-drug conjugates (ADCs) targeting the RON receptor, a tumorigenic factor contributing to cancer malignancy, has been considered as a novel strategy for cancer therapy. Here we describe a humanized anti...

    Authors: Xiang-Min Tong, Liang Feng, Sreedhar Reddy Suthe, Tian-Hao Weng, Chen-Yu Hu, Yi-Zhi Liu, Zhi-Gang Wu, Ming-Hai Wang and Hang-Ping Yao

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:250

    Content type: Research article

    Published on:

  36. PD-1/PD-L1 blockade has received approval for clinical application due to its encouraging benefit with improving prognosis in selected populations. Unfortunately, the response to immunotherapy for many patient...

    Authors: Fan Luo, Min Luo, Qi-Xiang Rong, Hong Zhang, Zhen Chen, Fang Wang, Hong-Yun Zhao and Li-Wu Fu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:245

    Content type: Research article

    Published on:

  37. Immune checkpoint blockade (ICB) promotes adaptive immunity and tumor regression in some cancer patients. However, in patients with immunologically “cold” tumors, tumor-resident innate immune cell activation m...

    Authors: Stefanie R. Mullins, John P. Vasilakos, Katharina Deschler, Iwen Grigsby, Pete Gillis, Julius John, Matthew J. Elder, John Swales, Elina Timosenko, Zachary Cooper, Simon J. Dovedi, Andrew J. Leishman, Nadia Luheshi, James Elvecrog, Ashenafi Tilahun, Richard Goodwin…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:244

    Content type: Research article

    Published on:

  38. Tumors can employ different mechanisms to evade immune surveillance and function. Overexpression of co-inhibitory ligands that bind to checkpoint molecules on the surface of T-cells can greatly impair the func...

    Authors: Shiran Hoogi, Vasyl Eisenberg, Shimrit Mayer, Astar Shamul, Tilda Barliya and Cyrille J. Cohen

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:243

    Content type: Research article

    Published on:

  39. The gut microbiome impacts the efficacy of immune checkpoint inhibitor (ICI) therapy and the development of ICI-mediated diarrhea and/or colitis (IMDC). Antibiotic therapy,especially that with anaerobic activity,...

    Authors: Hamzah Abu-Sbeih, Lauren Nicholas Herrera, Tenglong Tang, Mehmet Altan, Anne-Maria P. Chaftari, Pablo C. Okhuysen, Robert R. Jenq and Yinghong Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:242

    Content type: Research article

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:352

  40. HuMax-IL8 (now known as BMS-986253) is a novel, fully human monoclonal antibody that inhibits interleukin-8 (IL-8), a chemokine that promotes tumor progression, immune escape, epithelial-mesenchymal transition...

    Authors: Marijo Bilusic, Christopher R. Heery, Julie M. Collins, Renee N. Donahue, Claudia Palena, Ravi A. Madan, Fatima Karzai, Jennifer L. Marté, Julius Strauss, Margaret E. Gatti-Mays, Jeffrey Schlom and James L. Gulley

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:240

    Content type: Research article

    Published on:

  41. Preclinical evidence suggests that low-dose radiation may overcome the inhibitory effects of the tumor stroma and improve a tumor’s response to immunotherapy, when combined with high-dose radiation to another ...

    Authors: Hari Menon, Dawei Chen, Rishab Ramapriyan, Vivek Verma, Hampartsoum B. Barsoumian, Taylor R. Cushman, Ahmed I. Younes, Maria A. Cortez, Jeremy J. Erasmus, Patricia de Groot, Brett W. Carter, David S. Hong, Isabella C. Glitza, Renata Ferrarotto, Mehmet Altan, Adi Diab…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:237

    Content type: Research article

    Published on:

  42. T cell receptor-engineered T cells (TCR-Ts) therapy is a promising cancer treatment strategy. Nowadays, most studies focused on identification of high-avidity T cell receptors (TCRs) directed against neoantige...

    Authors: Qin Tan, Chaoting Zhang, Wenjun Yang, Ying Liu, Palashati Heyilimu, Dongdong Feng, Liying Xing, Yang Ke and Zheming Lu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:232

    Content type: Research article

    Published on:

  43. Myeloid-derived suppressor cells (MDSCs) are immunosuppressive cells that play an important role in immune evasion, PD-1/PD-L1 inhibitor tolerance and tumour progression. Therefore, MDSCs are potential targets...

    Authors: Wanfeng Gao, Xiaoyun Zhang, Wendong Yang, Daolei Dou, Heng Zhang, Yuanhao Tang, Weilong Zhong, Jing Meng, Yun Bai, Yanrong Liu, Lan Yang, Shuang Chen, Huijuan Liu, Cheng Yang and Tao Sun

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:231

    Content type: Research article

    Published on:

  44. T cell receptor (TCR) gene-engineered T cells have shown promise in the treatment of melanoma and synovial cell sarcoma, but their application to epithelial cancers has been limited. The identification of nove...

    Authors: Bridget Marcinkowski, Sanja Stevanović, Sarah R. Helman, Scott M. Norberg, Carylinda Serna, Benjamin Jin, Nikolaos Gkitsas, Tejas Kadakia, Andrew Warner, Jeremy L. Davis, Lisa Rooper and Christian S. Hinrichs

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:229

    Content type: Short report

    Published on:

  45. Samalizumab is a novel recombinant humanized monoclonal antibody that targets CD200, an immunoregulatory cell surface member of the immunoglobulin superfamily that dampens excessive immune responses and mainta...

    Authors: Daruka Mahadevan, Mark C. Lanasa, Charles Farber, Manjari Pandey, Maria Whelden, Susan J. Faas, Terrie Ulery, Anjli Kukreja, Lan Li, Camille L. Bedrosian, Xiaoping Zhang and Leonard T. Heffner

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:227

    Content type: Research article

    Published on:

  46. Immune checkpoint inhibitors (ICI) have demonstrated remarkable efficacy as cancer therapeutics, however, their use remains limited due to the development of immune related adverse events (irAEs). Immune relat...

    Authors: Yousef R. Badran, Justine V. Cohen, Priscilla K. Brastianos, Aparna R. Parikh, Theodore S. Hong and Michael Dougan

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:226

    Content type: Short report

    Published on:

  47. The safety, efficacy, pharmacokinetics, and pharmacodynamics of the anti-programmed cell death-1 antibody MEDI0680 were evaluated in a phase I, multicenter, dose-escalation study in advanced solid malignancies.

    Authors: Aung Naing, Jeffrey Infante, Sanjay Goel, Howard Burris, Chelsea Black, Shannon Marshall, Ikbel Achour, Susannah Barbee, Rena May, Chris Morehouse, Kristen Pollizzi, Xuyang Song, Keith Steele, Nairouz Elgeioushi, Farzana Walcott, Joyson Karakunnel…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:225

    Content type: Research article

    Published on:

  48. As part of the 2018 Immunotherapy Bridge congress (November 28–29, Naples, Italy), the Great Debate session featured counterpoint views from leading experts on four topical clinical issues in immunotherapy tod...

    Authors: Paolo A. Ascierto, Lisa H. Butterfield, Sandra Demaria, Robert L. Ferris, Gordon J. Freeman, Roger S. Lo, Alberto Mantovani, Paul Nathan, Omid Hamid, Katerina Politi and Igor Puzanov

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:221

    Content type: Review

    Published on:

  49. Erythropoietin-producing hepatocellular receptor A2 (EPHA2) is overexpressed on the cell surface in many cancers and predicts poor prognosis. DS-8895a is a humanized anti-EPHA2 IgG1 monoclonal antibody afucosy...

    Authors: Kohei Shitara, Taroh Satoh, Satoru Iwasa, Kensei Yamaguchi, Kei Muro, Yoshito Komatsu, Tomohiro Nishina, Taito Esaki, Jun Hasegawa, Yasuyuki Kakurai, Emi Kamiyama, Tomoko Nakata, Kota Nakamura, Hayato Sakaki and Ichinosuke Hyodo

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:219

    Content type: Research article

    Published on:

  50. Prostate cancer is poorly responsive to immune checkpoint inhibition, yet a combination with radiotherapy may enhance the immune response. In this study, we combined radiotherapy with immune checkpoint inhibit...

    Authors: Stephanie O. Dudzinski, Brent D. Cameron, Jian Wang, Jeffrey C. Rathmell, Todd D. Giorgio and Austin N. Kirschner

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:218

    Content type: Research article

    Published on:

Advertisement